Bio-Rad's Q2 Revenues Slip 2 Percent on Softness in Europe, Strengthening Dollar | GenomeWeb

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories said after the close of the market on Tuesday that revenues in the second quarter were down 2 percent year over year, as the firm missed analysts' estimate on the top line.

For the three months ended June 30, the Hercules, Calif.-based company recorded revenues of $510.4 million, down from $521.7 million and below the consensus Wall Street estimate of $524.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.